Get started
Author

Mariano Siguero

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
2014 · María Elena Elez, Josep Tabernero, et al. · Clinical Cancer Research · 89
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
2017 · E. Calvo, V. Moreno, et al. · Annals of Oncology · 85
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
2020 · Vivek Subbiah, Luis Paz-Ares, et al. · Lung Cancer · 41
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
2022 · Vivek Subbiah, Irene Braña, et al. · Clinical Cancer Research · 35
PDF
Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.
2019 · Luis G. Paz-Ares, Jose Manuel Trigo Perez, et al. · Journal of Clinical Oncology · 25
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors
2016 · Luis Paz-Ares, Martin Forster, et al. · Investigational New Drugs · 24
PDF
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
2012 · T A Yap, H Cortes-Funes, et al. · British Journal of Cancer · 21
PDF
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
2022 · Federico Longo-Muñoz, Daniel Castellano, et al. · European Journal of Cancer · 19
PDF
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
2012 · Christophe Massard, Jane Margetts, et al. · Investigational New Drugs · 18
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.
2020 · Santiago Ponce Aix, Gregory Michael Cote, et al. · Journal of Clinical Oncology · 16
Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.
2018 · Jose Manuel Trigo Perez, Alexandra Leary, et al. · Journal of Clinical Oncology · 14
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
2022 · V. Boni, B. Pistilli, et al. · ESMO Open · 11
A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors
2013 · Robin L. Jones, Stefano Ferrari, et al. · Investigational New Drugs · 11
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome
2018 · Christopher B. Benton, Kelly S. Chien, et al. · Hematological Oncology · 10
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
2022 · Emiliano Calvo, Cristiana Sessa, et al. · Investigational New Drugs · 9
PDF
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
2023 · Rebecca Kristeleit, Alexandra Leary, et al. · Investigational New Drugs · 8
PDF
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
2018 · Vivek Subbiah, Kamalesh Kumar Sankhala, et al. · Journal of Clinical Oncology · 8
A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
2013 · J. Capdevila, S. Clive, et al. · Cancer Chemotherapy and Pharmacology · 8
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
2021 · Rebecca Kristeleit, Victor Moreno, et al. · International Journal of Gynecological Cancer · 7
PDF
Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
2014 · Daniel E. Castellano, Joaquim Bellmunt, et al. · Cancer Chemotherapy and Pharmacology · 5
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors
2025 · Alejandro Falcón, Santiago Ponce, et al. · Investigational New Drugs · 4
PDF
Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
2022 · A.H. Awada, V. Boni, et al. · ESMO Open · 4
Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours
2019 · S Ponce Aix, M.J. Flor, et al. · Annals of Oncology · 4
Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC
2026 · Santiago Ponce, Miguel Ruiz-Torres, et al. · Journal of Thoracic Oncology · 3
P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials
2019 · S. Ponce, E. Calvo, et al. · Journal of Thoracic Oncology · 3
Works count: 42
Citation count: 491
H-index: 11
I10-index: 14
Year
Topic
Type